Lee Schwartzberg, MD, FACP, executive director, West Cancer Center, discusses his thoughts on calls for every person diagnosed with breast cancer to receive a multigene panel.
Lee Schwartzberg, MD, FACP, executive director, West Cancer Center, discusses his thoughts on calls for every person diagnosed with breast cancer to receive a multigene panel.
Transcript
New guidelines from the American Society of Breast Surgeons called for every person diagnosed with breast cancer to receive a multigene panel. Do you agree with this?
It’s a very complicated area who should be tested for a hereditary breast cancer gene. Today, we use panels, anywhere from 25 to 50 gene panels, which look at all the common and uncommon genes that have been identified that increase susceptibility to breast cancer. Of course, number 1 and 2 of those are BRCA1 & 2. Now we know that if you look for more genes and if you expand the criteria for looking at these genes that we’re going to find more people that have the potential for hereditary breast cancer and they can be offered prophylactic options, whether that’s surgery or increased surveillance or chemo prevention.
So, I think the American Society of Breast Surgeons took a very provocative stand because right now, if you look at the guidelines, they’re very confusing, and they’re kind of arbitrary, like NCCN [National Comprehensive Cancer Institute] says any patient under 45 should be tested but only patients between 45 and 50 who have certain family history and triple-negative patients under 60, so it’s very complicated and it probably doesn’t need to be that complicated. I definitely advocate for a broader testing.
However, we have to use our clinical judgment on whether or not we should test every 80-year-old diagnosed with breast cancer with zero family history. I think we can leave that up to the doctors, but I strongly agree with expanding the indications for comprehensive genetic testing in patients with breast cancer.
Standard Criteria for Loss of Ambulation Needed in DMD
April 19th 2024A recent study suggests the differences between ambulation definitions for patients with Duchenne muscular dystrophy (DMD) can impact the identification of ambulant vs nonambulant individuals, and standard criteria across settings are needed.
Read More
The Importance of Examining and Preventing Atrial Fibrillation
August 29th 2023At this year’s American Society for Preventive Cardiology Congress on CVD Prevention, Emelia J. Benjamin, MD, ScM, delivered the Honorary Fellow Award Lecture, “The Imperative to Focus on the Prevention of Atrial Fibrillation,” as the recipient of this year’s Honorary Fellow of the American Society for Preventive Cardiology award.
Listen
An Overview of Health Care and Pharmaceutical Trends, 2023-2024
April 19th 2024Douglas M. Long, BA, MBA, was featured as the keynote speaker on the closing day of The Academy of Managed Care Pharmacy 2024 annual meeting, with a session dedicated to surveying the health care and pharmaceutical trends of the last year.
Read More
Promoting Equity in Public Health: Policy, Investment, and Community Engagement Solutions
June 28th 2022On this episode of Managed Care Cast, we speak with Georges C. Benjamin, MD, executive director of the American Public Health Association, on the core takeaways of his keynote session at AHIP 2022 on public health policy and other solutions to promote equitable health and well-being.
Listen
Collecting SDOH Data Can Assess Risk of Medical Nonadherence, Improve HEI and Star Ratings
April 18th 2024At the Academy of Managed Care Pharmacy (AMCP) 2024 annual meeting, a panel of presenters explored changes coming to Medicare that incorporate social determinants of health (SDOH) data to improve patient and health system outcomes.
Read More